ERG245
ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology[1].
Product Specifications
UNSPSC
12352005
Target
Aminotransferases (Transaminases)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/erg245.html
Purity
99.49
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(CCC(C(C1=CC=C(Br)C=C1)=O)C2=CC=CC=C2)=O
Molecular Formula
C17H15BrO3
Molecular Weight
347.20
References & Citations
[1]Lodi F, et al. BCAT1 inhibition affects CD8+ T cell activation, exhaustion, and tumoral immunity by altering iron homeostasis[J]. bioRxiv, 2023: 2023.02. 25.530034.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR10451485 96 Well
Sheep B cell antigen receptor complex associated protein β chain (CD79B) ELISA kit
Sign In for Pricing
View Details 